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Abstract
Background: Epidermal growth factor receptor (EGFR) has been reported to downregulate E-cadherin (E-cad);
however, whether the downregulation of E-cad has any effect on EGFR expression has not been elucidated. Our
previous studies have found an inverse correlation between EGFR and E-cad expression in tissue specimens of
squamous cell carcinoma of the head and neck (SCCHN). To understand the biological mechanisms underlying this
clinical observation, we knocked down E-cad expression utilizing E-cad siRNA in four SCCHN cell lines.
Results: It was observed that downregulation of E-cad upregulated EGFR expression compared with control siRNA-
transfected cells after 72 hours. Cellular membrane localization of EGFR was also increased. Consequently,
downstream signaling molecules of the EGFR signaling pathway, p-AKT, and p-ERK, were increased at 72 hours
after the transfection with E-cad siRNA. Reverse transcriptase-polymerase chain reaction (RT-PCR) showed EGFR
mRNA was upregulated by E-cad siRNA as early as 24 hours. In addition, RT-PCR revealed this upregulation was
due to the increase of EGFR mRNA stability, but not protein stability. Sulforhodamine B (SRB) assay indicated
growth of E-cad knocked down cells was enhanced up to 2-fold more than that of control siRNA-transfected cells
at 72-hours post-transfection. The effect of E-cad reduction on cell proliferation was blocked by treating the E-cad
siRNA-transfected cells with 1 μM of the EGFR-specific tyrosine kinase inhibitor erlotinib.
Conclusion: Our results suggest for the first time that reduction of E-cad results in upregulation of EGFR
transcriptionally. It also suggests that loss of E-cad may induce proliferation of SCCHN by activating EGFR and its
downstream signaling pathways.
Background
Head and neck cancer (HNC) is the sixth most common
cancer and is responsible for almost 200,000 deaths
around the world each year [1,2]. There were an
estimated 48,010 new cases of HNC and 10,260 deaths
in the U.S alone in 2009 [3]. HNC presents as 90%
squamous cell carcinoma (SCC) and is a highly hetero-
geneous disease. Both locoregional recurrences and
lymph node metastasis (LNM) are associated with a
poor prognosis. Despite advances in understanding the
molecular mechanisms of HNC along with improved
diagnosis, the 5-year survival rate has been virtually
unchanged in the past 30 years, remaining at less than
50% for patients with a single ipsilateral lymph node
metastasis and less than 25% for patients with bilateral
metastasis. Therefore, better understanding of the biolo-
gical behavior of this disease could help to predict and
guide treatment of HNC.
Epidermal growth factor receptor (EGFR) is a 170 kDa
transmembrane protein with intrinsic tyrosine kinase
activity that regulates cell growth in response to binding
of its ligands, including epidermal growth factor (EGF)
and transforming growth factor-a (TGF-a). EGFR
overexpression has been documented extensively in a
wide variety of malignant tumors, including squamous
cell carcinoma of the head and neck (SCCHN) [4-11].
Overexpression of EGFR and its ligand TGF-a is
observed in 80 to 90% of SCCHN specimens [7,8,12-14].
Several studies have demonstrated that EGFR overex-
pression correlates with reduced disease-free and overall
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any medium, provided the original work is properly cited.survival [6,9,10,12]. Therefore, many strategies including
using specific tyrosine kinase inhibitors (TKI) and
monoclonal antibodies to target EGFR have been devel-
oped for treatment of SCCHN.
E-cadherin (E-cad) is a cell-cell adhesion transmem-
brane molecule. It plays important roles not only in cell
adhesion and morphogenesis, but also in cellular signal
transduction in collaboration with EGFR/ERK and
c-Src-mediated pathways. In addition, loss of E-cad
results in the translocation of b-catenin into the
nucleus, permitting direct and indirect regulation of
transcription. It has also been shown that loss of E-cad
is involved in epithelial-mesenchymal transition (EMT)
which is the hallmark for cancer metastasis [15]. E-cad
expression in SCCHN tissue specimens has been
reported in several studies. Together, these studies have
demonstrated the essential roles of EGFR and E-cad in
SCCHN cancer development and progress.
Previous studies have indicated there are cross-talks
between the E-cad and EGFR pathways regulating the
growth of various types of cancer. It has been demon-
strated that activation of EGFR reduced E-cad levels
through the E-cad suppresser gene TWIST [16]. E-cad
has been reported to bind to EGFR via the extracellular
domain of both proteins, and as such inhibit its activa-
tion. Lugo-Martínez et al have shown that activation of
EGFR was detected in detached enterocytes before the
disappearance of E-cad, and that endocytosis of E-cad
depended on the tyrosine-kinase activity of EGFR [17].
These results indicate that a mutual regulation exists
between E-cad and EGFR. Although this has been
studied intensely, it remains unknown whether the
reduction of E-cad has any regulatory effect on EGFR in
terms of both expression and function.
Our own studies have shed light on the expression
and cellular localizationo fE G F Ra n dE - c a di nb o t h
tumor specimens and SCCHN cell lines [18,19]. Three
patterns in the tumor samples were observed, in which
48% showed overexpression of EGFR and reduced
expression of E-cad. SCCHN patients with this expres-
sion pattern also demonstrated shorter disease-free and
overall survival than the patients with the two other pat-
terns [18]. To understand the biology behind this obser-
vation and its implication for SCCHN, we used siRNA
to reduce E-cad expression to determine whether down-
regulation of E-cad has any effect on EGFR expression
and function, which may consequently accelerate
SCCHN cell proliferation.
Methods
Cell Culture
Four E-cad highly-expressing SCCHN cell lines were
used in these studies. Tu686 and 686LN were estab-
lished from a primary base of tongue SCC and its
lymph node metastasis, respectively [20]. Tu212 was
established from a primary hypopharyngeal SCC [21].
UPCI-37A was established from SCC in the larynx
(epiglottis) at the University of Pittsburgh Cancer Insti-
tute [22]. The cell lines were maintained as monolayer
cultures in Dulbecco’s modified Eagle’sm e d i u m
(DMEM)/F12 medium (1:1) supplemented with 10%
fetal bovine serum (FBS) at 37°C in a humidified atmo-
sphere with 5% CO2.
Reduction of E-cad by siRNA
Cells were seeded at a concentration of 1.5 × 10
5/well in
12-well cell culture plates 12 hrs before transfection.
Both E-cad siRNA (siGENOME SMART pool, Cat#
M-003877-02) and non-targeted control siRNA (siCON-
TROL, Cat# D-001210-01) (Thermo Scientific Dharma-
con, Chicago, IL) were transfected using HiPerFect
transfection reagent (Qiagen, Valencia, CA) according to
the manufacturer’s instruction. The effects on E-cad
reduction of the transfection were evaluated by Western
blot and flow cytometry analysis as described below.
Western Blot Analysis
Cells were washed twice with phosphate buffered saline
(PBS) before being lysed on ice for 30 min with lysis
buffer containing 50 mmol/L HEPES buffer, 150 mmol/
L NaCl, 1 mmol/L EDTA (pH 8.0), 1 mmol/L EGTA
(pH8.0), 1% IGEPAL CA-630, 0.5% Triton X-100, 10
mmol/L NaF, 2 mmol/L Na3VO4, 10 mmol/L b-glycero-
phosphate and 1% Protease Inhibitor Cocktail (Sigma-
Aldrich, St Louis, MO). The lysate was centrifuged at
16,000 g at 4°C for 15 min. Fifty micrograms of total
protein for each sample were separated by 10% SDS-
PAGE and transferred onto a polyvinylidene difluoride
membrane (Bio-Rad Labs, Hercules, CA), and the
desired proteins were probed with corresponding anti-
bodies. Mouse anti-E-cad (clone G-10, 1:1000 dilution)
and rabbit anti-EGFR (clone 1005, 1:500 dilution) anti-
bodies were purchased from Santa Cruz Biotechnology.
Phospho-p42/44 MAPK (Thr202/Tyr204) and phospho-
AKT (Ser473) antibodies were purchased from Cell Sig-
naling Technology. Antibody for phospho-EGFR
(Tyr1173, 1:500 dilution) was purchased from Upstate.
GAPDH (1:3000 dilution, Trevigen, Inc., Gaithersburg,
MD) was used as an internal control. HRP-conjugated
secondary antibodies were anti-Rabbit IgG (H+L) and
anti-Mouse IgG (H+L) (Promega, Madison, WI). Bound
antibody was detected using the SuperSignal West Pico
Chemoluminescence system (Pierce, Inc., Rockford, IL).
Flow Cytometric Analysis
To quantify EGFR expression on the cell membrane,
flow cytometric analysis of cell surface staining was
performed. After dissociation with Cell Stripper™
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6 cells were incubated
with monoclonal mouse-anti-EGFR (R-1, 1:200 dilution,
Santa Cruz) for 45 min at room temperature. Mouse
IgG was used as an isotype control. After washing, the
cells were incubated with Alexa Fluor
® 488 goat anti-
mouse IgG (H+L) highly cross-absorbed antibody (1:200
dilution, Molecular Probe). Cells were resuspended in 1
ml 2% BSA to run flow cytometry analysis with FACS-
can (BD). Data were analyzed by the software FlowJo
(Ashland, OH).
RT-PCR and Real-Time PCR
Total RNA of siRNA-transfected cells was isolated with
Trizol reagent (Invitrogen, Carlsbad, CA) and reverse
transcription was performed by using iScript™ cDNA
Synthesis Kit (Bio-Rad) according to the manufacturer’s
protocol. PCR was performed using Taq DNA Polymer-
ase High Fidelity (Invitrogen) with the primers indicated
below. Forward primer for EGFR: 5’-TGTTT GGGAC
CTCCG GTCAG-3’ and reverse primer for EGFR:
5’-GGCAG GTCTT GACGC AGTGG-3’.G A P D Hw a s
also amplified as the internal control with the following
primers: forward: 5’-ATGTT CGTCA TGGGT GTGAA
CCA-3’ and reverse: 5’-TGGCA GGTTT TTCTA
GACG GCAG-3’. All samples were first denatured at
94°C (5 min) and the PCR reaction then allowed to pro-
ceed for 25 (GAPDH) and 30 (EGFR) amplification
cycles: denaturation (45 sec, 94°C), annealing (1 min at
57°C) and extension (1 min at 72°C). Then, a final
extension step of 10 min at 72°C was performed. EGFR
and GAPDH mRNA level was quantified using UVP
BioImaging System, (Upland CA) to measure the density
of specific cDNA band.
For real-time PCR, equal amounts of total mRNA
from E-cad knock-down cells and control cells were
used to amplify cDNA. EGFR and GAPDH cDNAs were
amplified with iQ SYGR Green Supermix (Bio-Rad, Her-
cules CA) using the same primers as described above.
The reaction mixture consisted of 0.5 μl of cDNA, 25 μl
of iQ SYGR Green Supermix, 0.2 μM of target primers
in a total volume of 50 μl. Amplification was carried out
at 10 min at 95°C for polymerase activation, and 35
cycles of 95°C for 15 s (denaturation) and 56°C for 1
min (annealing and extension) on the IQ5 real-time
detection system (Bio-Rad). The amount of EGFR
mRNA was normalized to human GAPDH as an inter-
nal control. Experiments were repeated 3 times. Error
bars represent standard deviation.
EGFR mRNA Stability Assay
A set of siRNA transfected cells were re-seeded in a 12-
well plate 24 hrs after the transfection. After settling,
the cells were exposed to actinomycin-D (Sigma-
Aldrich) at 5 μg/ml. RNA was harvested at 0, 4 hrs,
8 hrs, and 24 hrs. The levels of EGFR mRNA were
determined by RT-PCR as described above.
EGFR Protein Stability Assay
A set of siRNA transfected cells were re-seeded in a 12-
well plate 24 hrs after the transfection. After settling,
the cells were exposed to cycloheximide (CHX) (Sigma-
Aldrich) at 10 μg/ml. RNA was harvested at 0, 1 hr, 3
hrs, and 24 hrs. The levels of EGFR protein were deter-
mined by Western blot analysis as described above.
Cell Growth Assay (SRB assay)
Sulforhodamine B (SRB) assay was used for cell growth
determination. siRNA-transfected cells were re-seeded
in a 96-well plate 24 hrs after the transfection at a
d e n s i t yo f5×1 0
3 cells/well. Cells were fixed with 10%
trichloroacetic acid after another 24, 48, or 72 hrs of
culture. Cells then were washed 5 times with distilled
and de-ionized water. After air drying, 50 μlS R Bw a s
added to the cells and incubated for 10 min. Cells were
then washed with 1% acetic acid 5 times. After air dry-
ing, 10 mM Tris solution (pH 10) was added to dissolve
the bound dye. The cell growth was assessed by optical
density (OD) determination at 510 nm using a micro-
plate reader. For the TKI study, 1 μM erlotinib was
added 24 hrs after cells were transfected with siRNA.
SRB assay was carried out 48 and 72 hrs after erlotinib
treatment.
Results
Downregulation of E-cad enhanced EGFR expression
mainly through stabilization of EGFR mRNA
Expression levels of EGFR and E-cad were initially
examined in four SCCHN cell lines: Tu686, 686LN,
Tu212, and PCI-37A (Figure 1a). To determine whether
the reduction of E-cad has any effect on EGFR expres-
sion level, and the mechanism of the possible regulation
of EGFR by E-cad, we transfected two SCCHN cell
lines, 686LN and PCI-37A with siRNA against E-cad.
Western blot was performed to measure the change in
EGFR protein level. It was shown that reduction of
E-cad by siRNA increased the total protein levels of
EGFR. The fold changes in total EGFR as compared
with the control were 1.85 ± 0.2 and 2.1 ± 0.2 for
686LN and PCI-37A, respectively, based on three
experiments (Figure 1b). The control siRNA did not
have any effect on E-cad expression (see additional file
1). Upregulation of EGFR expression was also observed
using a shRNA strategy targeting a different sequence to
knock down E-cad (see additional file 2). At the same
time, the amount of EGFR on the cellular membrane
was also enhanced (Figure 1c). The fold changes in the
level of cell surface EGFR as compared with the control
were 1.22 ± 0.03 and 1.48 ± 0.07 for 686LN and
Wang et al. Molecular Cancer 2011, 10:116
http://www.molecular-cancer.com/content/10/1/116
Page 3 of 10PCI-37A cells, respectively, suggesting that increased
EGFR on the surface after E-cad knockdown results
mainly from the increase in total EGFR expression.
EGFR upregulation was found as early as 24 hours after
the siRNA treatment (Figure 2). RT-PCR was further
performed to measure the change in EGFR mRNA
levels. As shown in Figure 3, the mRNA level was upre-
gulated in 3 out of 4 cell lines. To demonstrate the
mechanism underlying the upregulation of EGFR by E-
cad reduction, both PCI-37A and 686LN cells were trea-
ted with actinomycin D or cycloheximide (CHX). As
s h o w ni nF i g u r e4 aa n d4 b ,t h er a t i oo fE G F Rm R N A
level between E-cad knockdown and the control cells
increased from 0 to 24 h after actinomycin D treatment
(1.3 ± 03, 2.9 ± 0.4, 3.2 ± 0.8, and 3.3 ± 0.6 after 0, 4, 8,
and 24 hours, respectively, in PCI-37A cells). This result
was confirmed by quantitative real-time PCR which
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Figure 1 Reduction of E-cad by siRNA increased the levels of total EGFR and cell surface EGFR in both 686LN and PCI-37A cells.( a )
Basal E-cad and EGFR expression in 4 SCCHN cell lines. (b) Both E-cad siRNA and non-targeted control siRNA were transfected using HiPerFect
transfection reagent. The effects of E-cad reduction by siRNA transfection on EGFR expression at the protein level were evaluated by Western
blot. At 72 hours after the transfection, EGFR protein levels were clearly increased in both 686LN and PCI-37A cells. (c). To quantify EGFR
expression on the cell membrane, flow cytometric analysis of cell surface staining was performed. The cells transfected with siRNA (48 hrs after
transfection) were incubated with monoclonal mouse-anti-EGFR antibody (Santa Cruz). The level of EGFR protein on the cell surface was
examined by flow cytometry analysis using FACScan (BD). Data were analyzed by the software FlowJo (Ashland, OH). Data indicate that in both
686LN and PCI-37A cells, the level of cell surface EGFR protein was significantly increased upon reduction of E-cad based on three
measurements (p < 0.001 for both cell lines). Error bars represent standard deviation.
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GAPDH
EGFR
12h 24h 48h
siRNA
Figure 2 EGFR upregulation can be detected as early as 24
hours in E-cad siRNA transfected cells. Cell lysate from PCI-37A
cells was collected at 12, 24, and 48 hours after transfection with E-
cad and control siRNAs. 50 μg protein was loaded for SDS-PAGE,
and Western blot analysis was performed using EGFR antibody. The
result showed EGFR protein was upregulated as early as 24 hours
after siRNA was transfected.
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Page 4 of 10showed that the ratios of EGFR mRNA level in E-cad
knockdown cells against the control cells were 1.8 ±
0.16, 2.5 ± 0.30, 2.7 ± 0.29, and 2.6 ± 0.21 at different
t i m ep o i n t s :0 ,4 ,8 ,a n d2 4h o u r s ,r e s p e c t i v e l y
(Figure 4c), suggesting thatE G F Rm R N As t a b i l i t yw a s
increased in E-cad knockdown cells compared with the
control cells. The same result was also observed when
shRNA was used to knock down E-cad expression (see
additional file 3).
On the other hand, EGFR protein stability was not
changed by CHX treatment for up to 4 hours (28 hours
after addition of E-cad siRNA), but was affected in the
knock-down cells at 12 hours after the treatment with
Ctrl        E-Cad        Ctrl        E-Cad        Ctrl        E-Cad       Ctrl         E-Cad
Tu686 686LN 37A Tu212
EGFR
GAPDH
siRNA
Figure 3 Reduction of E-cad by siRNA increased EGFR mRNA in
SCCHN cell lines. Both E-cad siRNA and non-targeted control
siRNA were transfected using HiPerFect transfection reagent. The
EGFR mRNA level was evaluated 24 h after the transfection by RT-
PCR. RT-PCR on GAPDH was performed at the same time as a
control. Three out of four cell lines (Tu686, 686LN, PCI-37A) showed
increased expression of EGFR mRNA.
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Figure 4 Knockdown of E-cad increased EGFR expression by enhancing its mRNA stability. (a) 24 hours after transfection of PCI-37A and
686LN cells with siRNA, cells were treated with actinomycin-D (Sigma-Aldrich) at 5 μg/ml for 0, 4, 8 and 24 hours. RT-PCR showed that the EGFR
mRNA level remained higher in E-cad knockdown cells than in the control cells even after mRNA synthesis was stopped by actinomycin-D for 24
hours. (b) EGFR and GAPDH mRNA level as PCR products were measured using UVP BioImaging System Representative. The ratios of EGFR
mRNA levels in E-cad knockdown cells (PCI-37A) against that in control cells at different time points were determined after being normalized to
GAPDH. (c) Real-time RT-PCR on PCI-37A cells confirmed the ratios of EGFR mRNA level in E-cad knockdown cells against the control cells at
different time points. These results indicate that EGFR mRNA stability was enhanced in E-cad knockdown cells. The experiments were repeated 3
times. Error bars represent standard deviation.
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This suggests that the overall effect of loss E-cad on
total EGFR may be a balance between the two contra-
dictory consequences, stabilizing the mRNA, but
degrading protein.
Elevated EGFR protein by reduction of E-cad resulted in
activation of EGFR-mediated signaling pathways
Our western blot results show that as E-cad is knocked
down, the EGFR phosphorylation level at y1045 and
y1173 increases in proportion to the increase in protein
level (Figure 6). The increase in phosphorylation of
EGFR can elicit activation of downstream signaling
through several proteins. The involvement of AKT and
ERK in EGFR-dependent phosphorylation cascades has
long been recognized. To assess the role of the loss of
E-cad in the EGFR signaling pathway, Western blot was
carried out to analyze the alteration of these down-
stream target proteins of EGFR. Western blot results
showed that both the phosphorylation levels of AKT
and ERK were significantly increased by the reduction
of E-cad (Figure 6), but the total levels of both AKT and
ERK were not changed, suggesting that reduction of E-
cad not only increased the protein and phosphorylation
level of EGFR but also activated the downstream targets
of EGFR. The same phenomena were observed using
the shRNA strategy (see additional file 2).
Downregulation of E-cad stimulated cell proliferation
through activation of EGFR
O n eo ft h er e s u l t so ft h ea c t i v a t i o no fE G F Ra n di t s
downstream proteins is to initiate several signal trans-
duction cascades and DNA synthesis followed by cell
proliferation. To investigate the effect of reduction of E-
cad on cell proliferation, we performed an SRB assay to
assess cell growth after transfection with E-cad-specific
siRNA. As shown in Figure 7, reduction of E-cad by
siRNA increased the proliferation level of SCCHN cell
lines by 1.25 to 1.5-fold in both PCI-37A and 686LN
cells. To determine if the proliferation effect of E-cad
reduction was EGFR dependent, we treated the siRNA-
transfected cells with erlotinib, an EGFR-tyrosine kinase
inhibitor (EGFR-TKI). Erlotinib clearly reduced the pro-
motive effect of E-cad loss on cell proliferation.
Discussion
EGFR overexpression and E-cad loss are the major char-
acteristics of aggressive cancers [5,6,18,23,24]. It has
been documented that these two characteristics are
related and are identified as one of the major patterns
in clinical tissue samples of SCCHN [18]. It has long
been known that E-cad is involved in cancer progres-
sion. Loss of E-cad is related to cancer invasion and
metastasis of SCCHN. However, how this loss of E-cad
functions to promote cancer progression is still not
completely elucidated. In this study, we demonstrate for
the first time that loss of E-cad transcriptionally upregu-
lates EGFR; the induced proliferation of SCCHN cells
by loss of E-cad occurs at least partially through the
activation of EGFR and its downstream signaling
pathways.
EGFR is known to diminish E-cad expression by ele-
vating MMP-9 activity. EGFR activation induces MMP-9
expression and activation, which in turn disrupts adhe-
sion junction and protein level of E-cad [23]. On the
other hand, previous studies have also shown that E-cad
GAPDH
EGFR
E-Cad
686LN 37A 
CNT CNT E-Cad E-Cad
CHX 0       2      4     12 0      2      4       12  0      2        4     12 0      2      4      12h
siRNA
Figure 5 Knockdown of E-cad did not increase EGFR protein stability. 24 hours after PCI-37A and 686LN cells were transfected with siRNA,
cells were treated with cycloheximide (CHX) (Sigma-Aldrich) at 10 g/ml for 0, 2, 4 and 12 hrs. The EGFR protein level remained unchanged for
up to 4 hours, and then declined after 12 hours of treatment with CHX in the tested SCCHN cell lines with E-cad knockdown. The experiment
was repeated once. Activity of CHX was confirmed with a protein known to be regulated at the transcriptional level by Western analysis.
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Qian et al showed that E-cad could inhibit cellular
responses to EGFR stimulation [25]. They observed that
mitogenic responsiveness to EGF decreased as cells
grew to confluence. This desensitization could be over-
come by adding antibodies that block E-cad function.
They also showed reduction of E-cad increased both
EGFR autophosphorylation and EGF-induced DNA
synthesis. Perrais et al further demonstrated that E-cad
homophilic ligation inhibited serum-stimulated cell pro-
liferation by preventing E-cad binding to b-catenin [26].
They also demonstrated that E-cad ligation inhibited
EGF-induced cell proliferation. E-cad homophilic liga-
tion disrupted the ability of EGFR to activate DNA
E-Cad
EGFR
p-EGFR(1173)
p-EGFR(1045)
p-AKT
p-ERK
GAPDH
686LN 37A
AKT
ERK
siRNA
Figure 6 Elevated EGFR protein by reduction of E-cad resulted in activation of EGFR-mediated signaling pathways. Levels of
phosphorylated AKT, phosphorylated ERK and phosphorylated EGFR were analyzed by Western blot. In both 686LN and PCI-37A cells, enhanced
EGFR phosphorylation was observed after transfection of E-cad siRNA. Phosphorylated AKT and phosphorylated ERK levels were also increased
without alteration of the total protein levels. These results indicate that E-cad knockdown activated the EGFR-mediated signaling pathway. Data
presented are one result of 3 tests.
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on the mutual regulation of EGFR and E-cad, none have
addressed whether the loss of E-cad, which is one of the
most important features of EMT, has any effect on
EGFR expression.
To demonstrate whether E-cad loss has any effect on
EGFR expression and function, we knocked down E-cad
expression by siRNA in four SCCHN cell lines. We then
checked both mRNA and protein levels of EGFR in
these transfected cells. Our results showed that both
mRNA and protein levels of EGFR were upregulated
when E-cad was knocked down. We further found that
E-cad loss upregulated EGFR mRNA level by increasing
its mRNA stability. Most likely, loss of E-cad affects
EGFR mRNA stability indirectly since upregulation of
EGFR was observed 24 hours after applying E-cad
siRNA, which deserves further investigation. Currently,
we cannot rule out whether loss of E-cad may also
enhance EGFR transcription through upregulating tran-
scription factors. There was no direct interaction
observed between EGFR and E-cad in the tested cell
lines by immunopreciptation (data not shown). It is still
possible that ablation of E-cad stimulates EGFR expres-
sion through other proteins. Another mechanism by
which high level EGFR expression could be sustained is
through increased protein stability; however, we did not
obtain any evidence in this regard.
We investigated whether the EGFR-mediated signaling
pathway is affected by E-cad-mediated regulation. After
E-cad was knocked down, the cellular membrane locali-
zation of EGFR was increased in addition to total EGFR
protein, which prepares EGFR to be ready to respond to
stimuli by EGFR ligands. This result suggests that E-cad
loss could not only increase EGFR expression but also
could have functional effects on the EGFR signaling
pathway, but current experiments cannot prove whether
the upregulation of EGFR expression is solely responsi-
ble for the observed activation of EGFR signaling. Our
Western blot analysis showed that downstream signaling
molecules of EGFR, p-AKT, and p-ERK, were increased
at 72 hours after treatment with E-cad siRNA without a
change in their total protein levels. AKT and ERK are
the major signal mediators downstream of the EGFR
pathway. The EGFR-Ras-Raf-MEK-ERK signaling
Figure 7 Cell growth induced by E-cad knockdown can be inhibited by EGFR tyrosine kinase inhibitor. Sulforhodamine B (SRB) assay was
used for cell growth determination. E-cad siRNA-transfected PCI-37A and 686LN cells were re-seeded in a 96-well plate 24 hrs after the
transfection. To check whether activation of EGFR contributed to cell proliferation, reseeded transfected cells were treated with 1 μM EGFR-
specific tyrosine kinase inhibitor erlotinib for 48 or 72 hrs followed by fixation with 10% trichloroacetic acid and SRB assay. The OD at 510 nm
was determined as absorbance value. The results showed that E-cad knockdown clearly induced cell growth, which, however, could be inhibited
by treatment with 1 μM erlotinib. Data presented are 1 of 3 repeated independent experiments. Error bars represent standard deviation.
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pharmaceutical scrutiny to identify novel target-based
approaches for cancer treatment (24). AKT, which
affects tumor cell motility and invasiveness, is also part
of the EGFR-associated signaling network. Our results
indicate that E-cad is probably involved in regulation of
both EGFR-ERK and EGFR-AKT pathways, resulting in
SCCHN cancer cell proliferation.
As speculated, the SRB assay showed that the growth
rate of E-cad knockdown cells increased up to 2-fold
more than that of control siRNA-transfected cells after
96 hours. The effect of E-cad reduction on cell prolifera-
tion was blocked by treating the E-cad siRNA-trans-
fected cells with 1 μM of the EGFR-specific TKI
erlotinib. These results support that E-cad loss has a sig-
nificant effect on EGFR function as well as expression in
SCCHN. They also indicate that the effect of E-cad
knockdown on cell proliferation was at least partly
dependent on EGFR activation.
EMT has been extensively studied because of its essen-
tial role in cancer metastasis. Loss of E-cad is a hallmark
of EMT. Lo et al reported that EGFR activation by EGF
led to EMT, an early event in carcinogenesis, and loss of
E-cad by activation of TWIST through a STAT3-mediated
pathway [16]. Snail is widely regarded as the suppressor of
E-cad, the driving force behind EMT [27,28]. Activation of
EGFR results in overexpression of Snail [29]. Our findings
suggested that loss of E-cad induces EGFR expression. It is
also possible that TWIST and Snail could be further acti-
vated in EMT as a result of overexpression of EGFR
downstream of E-cad ablation, thus sustaining the EMT
process. Additional studies certainly need to be done to
address if this is the case. Taken together, our data clearly
demonstrate that downregulating E-cad transcriptionally
increases EGFR expression as well as its function. These
results suggest that reduction of E-cad contribute to
SCCHN cancer progression and malignancy not just by
decreasing the strength of cellular adhesion, which results
in an increase in cellular motility and cancer metastasis,
but also by increasing EGFR expression and consequently
its downstream signaling pathway, leading to enhanced
cancer cell proliferation. Most importantly, this current
work for the first time has demonstrated that loss of E-cad
affects EGFR expression by increasing its mRNA stability.
Additional material
Additional file 1: Control siRNA does not affect E-cad expression in
4 cell lines. After 686LN, TU212, TU686 and 37A cells were transfected
with control siRNA for 24 hours, cell lysates from wild type cells and
transfected cells were collected; 50 μg protein was loaded for Western
blot to analyze the E-cad expression. b-actin expression was also
detected as a loading control. Our data indicate that the control siRNA
has no effect on E-cad expression. Data presented are one result of 3
separate experiments.
Additional file 2: Elevated EGFR protein by reduction of E-cad using
pLKo.1 shRNA E-cad resulted in activation of EGFR-mediated
signaling pathways. Levels of phosphorylation of EGFR at y1173 and
y1068, phosphorylated AKT, and phosphorylated ERK were analyzed by
Western blot. In both 686LN and PCI-37A cells, enhanced EGFR
phosphorylation was observed after transfection of pLKo.1 shRNA E-cad
targeting sequence 5’-gcagaaattattgggctcttt-3’ (Addgene Inc Cambridge,
MA). Phosphorylated AKT and phosphorylated ERK levels were also
increased without alteration of the total protein levels. Data presented
are one representative out of three repeated experiments.
Additional file 3: Knockdown of E-cad with pLKO.1 shRNA E-cad
increased EGFR expression by enhancing its mRNA stability. After
PCI-37A and 686LN cells were transfected with the pLKo.1 shRNA E-cad
(see additional file 2) for 24 hours, cells were treated with actinomycin-D
(Sigma-Aldrich) at 5 μg/ml for 0, 4, 8 and 24 hours. RT-PCR showed that
the EGFR mRNA level remained higher in E-cad knockdown cells than in
the pLKO.1-transfected control cells after mRNA synthesis was stopped
by actinomycin.
Abbreviations
EGFR: Epidermal growth factor receptor; E-cad: E-cadherin; SCCHN:
squamous cell carcinoma of the head and neck; SRB: Sulforhodamine B
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